DOI: https://doi.org/10.22141/2224-0713.1.87.2017.96536

Immunoglobulin therapy in autoimmune diseases of the peripheral nervous system

D.V. Maltsev, S.K. Evtushenko

Abstract


The autoimmune peripheral nervous system diseases, such as Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy, are highly sensitive to the normal human intravenous immunoglobulins, and the validity of the administration of immunotherapy in these cases is of the highest level of evidence А thanks to the results of a specially-designed randomized clinical trials. This article presents evidence on the efficacy and safety of intravenous immunoglobulin in autoimmune lesions of the peripheral nervous system, both on the basis of EFNS expert recommendations regulating the use of immunoglobulin therapy in neurology in the European Union, and the results of new clinical studies conducted after 2008, when these recommendations were published.


Keywords


autoimmune neuropathy; intravenous immunoglobulin; immunotherapy

References


Мальцев Д.В. Ассоциация аутоиммунных демиелинизирующих болезней нервной системы с гуморальными иммунодефицитами: новый ключ к пониманию эффективности иммуноглобулинотерапии // Международный неврологический журнал. — 2014. — № 2 (64). — С. 27-32.

Мальцев Д.В. Малі імунодефіцитні хвороби. — К.: Центр учбової літератури, 2015. — 460 с.

Неврология раннего детского возраста / Под ред. проф. С.К. Евтушенко. — К.: Издатель Заславский А.Ю., 2016. — 287 с.

Azulay J.-P., Blin O., Pouget J. et al. Intravenous immunoglobulin treatment in patientswith motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study // Neurology. — 1994. — Vol. 44. — P. 429-432.

Baumann A., Hess C.W., Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up // J. Neurol. — 2009. — Vol. 256 (4). — P. 608-614.

Carpo M., Cappellari A., Mora G. et al. Deterioration of multifocal motor neuropathyafter plasma exchange // Neurology. — 1998. — Vol. 50. — P. 1480-1482.

Charra B., Hachimi A., Benslama A., Motaouakkil S. Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome // Pan. Afr. Med J. — 2014. — Vol. 18. — P. 35.

Chaudhary A., Ramchand T., Frohman L.P. Miller Fisher variant of Guillain-Barré syndrome masquerading as acute sphenoid sinusitis with orbital apex syndrome // Laryngoscope. — 2012. — Vol. 122 (5). — P. 970-972.

Cho Y.Y., Joung J.Y., Jeong H. et al. Postinfectious Guillain-Barre syndrome in a patient with methimazole-induced agranulocytosis // Korean. J. Intern. Med. — 2013. — Vol. 28 (6). — P. 724-727.

Ciric B., Van Keulen V., Paz Soldan M., Rodriguez M., Pease L.R. Antibody-mediated remyelinationoperates through mechanism independent of immunomodulation // Journal of Neuroimmunology. — 2004. — Vol. 146. — P. 153-161.

Claus D., Specht S., Zieschang M. Plasmapheresis in multifocal motor neuropathy: a casereport // Journal of Neurology, Neurosurgery and Psychiatry. — 2000. — Vol. 68. — P. 533-535.

Consensus Conference. The utility of therapeutic plasmaphe-resis for neurological disorders. NIH Consensus Development // The Journal of the American Medical Association. — 1986. — Vol. 256. — P. 1333-1337.

Diener H.C., Haupt W.F., Kloss T.M. et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome // European Neurology. — 2001. — Vol. 46. —

P. 107-109.

Donaghy M., Mills K.R., Boniface S.J. et al. Pure motor demyelinating neuropathy: deteriorationafter steroid treatment and improvement with intravenous immuno-globulin // Journal of Neuro-

logy, Neurosurgery and Psychiatry. — 1994. — Vol. 57. — P. 778-783.

Dyck P.J., Litchy W.J., Kratz K.M. et al. A plasma exchange versus immune globulin infusiontrial in chronic inflammatory demyelinating polyradiculoneuropathy // Annals of Neurology. — 1994. — Vol. 36. — P. 838-845.

Elovaara I., Apostolski S., van Doorn P. et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases // Eur. J. Neurol. — 2008. — Vol. 15 (9). — P. 893-908.

Fergusson D., Hutton B., Sharma M. et al. Use of intravenous immunoglobulin for treatmentof neurological conditions: a systematic review // Transfusion. — 2005. — Vol. 45. — P. 1640-1657.

Fokkink W.J., Selman M.H., Dortland J.R. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins // J. Proteome Res. — 2014. — Vol. 13 (3). — P. 1722-1730.

Fokkink W.R., Walgaard C., Kuitwaard K. et al. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome // JAMA Neurol. — 2016. Dec 27. [Epub ahead of print].

Gallia F., Balducci C., Nobile-Orazio E. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies // J. Peripher. Nerv. Syst. — 2016. — Vol. 21 (2). — P. 82-84.

Gurses N., Uysal S., Cetinkaya F., Icslek I., Kalayci A.G. Intravenous immunoglobulintreatment in children with Guillain-Barré syndrome // Scandinavian Journal of Infectious Diseases. — 1995. — Vol. 27. — P. 241-243.

Hahn A.F., Bolton C.F., Zochodne D.W., Feasby T.E. Intravenous immunoglobulin treatmentin chronic inflammatory demyelinating polyneuropathy. A double-blind, placebocontrolled, cross-over study // Brain. — 1996. — Vol. 119. — P. 1067-

Hahn A.F., Beydoun S.R., Lawson V. et al. A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy // J. Peripher. Nerv. Syst. — 2013. — Vol. 18 (4). — P. 321-330.

Harbo T., Andersen H., Hess A. et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial // Eur. J. Neurol. — 2009. — Vol. 16 (5). — P. 631-638.

Hughes R.A.C. Treatment of Guillain-Barré syndrome with corticosteroids: lack of benefit? // Lancet. — 2004. — Vol. 363. — P. 181.

Hughes R.A.C., Bouche P., Cornblath D.R. et al. EFNS/PNS guideline on management ofchronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task forceof the European Fede-ration of Neurological Societies and the Peripheral Nerve Society // European Journal of Neurology. — 2006. — Vol. 13. — P. 326-332.

Hughes R.A.C., Cornblath D.R. Guillain-Barré syndrome // Lancet. — 2005. — Vol. 366. — P. 1653-1666.

Hughes R.A.C., Swan A.V., Raphael J.C. et al. Immunotherapy for Guillain-Barré syndrome: a systematic review // Brain. — 2007. — Vol. 130. — P. 2245-2257.

Hughes R.A., Bensa S., Willison H.J. et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy // Annals of Neurology. — 2001. — Vol. 50. — P. 195-201.

Hughes R.A., Donofrio P., Bril V. et al. Intravenous immune globulin (10 % caprylate chromatography purified) for the treatment of chronic inflammatory demyelinatingpolyradiculoneuropathy (ICE study): a randomised placebo-controlled trial // Lancet Neurology. — 2008. — Vol. 7. — P. 136-144.

Jacobs B.C., Van Doorn P.A., Schmitz P.I. et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome // Annals of Neurology. — 1996. — Vol. 40. —

P. 181-187.

Kanra G., Ozon A., Vajsar J., Castagna L., Secmeer G., Topaloglu H. Intravenous immunoglobulintreatment in children with Guillain-Barré syndrome // European Journal of Paediatric Neurology. — 1997. — Vol. 1. — P. 7-12.

Kleyweg R.P., Van der Meche F.G.A., Meulstee J. Treat-ment of Guillain-Barré syndromewith high-dose gammaglobulin // Neurology. — 1988. — Vol. 38. — P. 1639-1641.

Korinthenberg R., Schessl J., Kirschner J., Montning J.S. Intravenous immunoglobulin inthe treatment of child-hood Guillain-Barré syndrome // Pediatrics. — 2005. — Vol. 116. — P. 8-14.

Kuitwaard K., van den Berg L.H., Vermeulen M. et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy // J. Neurol. Neurosurg. Psychiatry. — 2010. — Vol. 81 (12). — P. 1374-1379.

Kumar P., Charaniya R., Bahl A. et al. Facial Diplegia with Paresthesia: An Uncommon Variant of Guillain-Barre Syndrome // J. Clin. Diagn. Res. — 2016. — Vol. 10 (7). — OD01-2.

Kuwabara S., Mori M., Ogawara K., Hattori T., Yuki N. Indicators of rapid clinical recoveryin Guillain-Barré syndrome // Journal of Neurology, Neurosurgery and Psychiatry. — 2001. — Vol. 70. — P. 560-562.

Latov N., Deng C., Dalakas M.C. et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy // Arch. Neurol. — 2010. — Vol. 67 (7). — P. 802-807.

Leger J.M., Chassande B., Musset L. et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlledstudy // Brain. — 2001. — Vol. 124. —

P. 145-153.

Leger J.M., Viala K., Cancalon F. et al. Intravenous immunoglobulin as short- and longterm therapy of multifocal motor neuropathy: a retrospective study of response to IVIGand of its predictive criteria in 40 patients // Journal of Neurology, Neurosurgery and Psychiatry. — 2008. — Vol. 79. — P. 93-96.

Maddur M.S., Rabin M., Hegde P. et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients // Immunol. Res. — 2014. — Vol. 60 (2-3). — P. 320-329.

Mendell J.R., Barohn R.J., Freimer M.L. et al. Rando-mized controlled trial of IVIG inuntreated chronic inflammatory demyelinating polyradiculoneuropathy // Neurology. — 2001. — Vol. 56. — P. 445-449.

Nobile-Orazio E. Multifocal motor neuropathy // Journal of Neuroimmunology. — 2001. — Vol. 115. — P. 4-18.

Nobile-Orazio E., Cocito D., Jann S. et al. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP // J. Neurol. Neurosurg. Psychiatry. — 2015. — Vol. 86 (7). — P. 729-734.

Nobile-Orazio E., Cocito D., Jann S. et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial // Lancet Neurol. — 2012. — Vol. 11 (6). —

P. 493-502.

Nomura K., Hamaguchi K., Hattori T. et al. A randomized controlled trial comparing intravenousimmunoglobulin and plasmapheresis in Guillain-Barré syndrome // Neurological Therapeutics. — 2001. — Vol. 18. — P. 69-81.

Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trialof plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome // Lancet. — 1997. — Vol. 349. — P. 225-230.

Raphael J.C., Chevret S., Harboun M., Jars-Guince-

stre M.C. French Guillain-Barré Syndrome Cooperative Group. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days // Journal of Neurology, Neurosurgery and Psychiatry. — 2001. — Vol. 71. — P. 235-238.

Ruts L., van Koningsveld R., Van Doorn P.A. Distin-guishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations // Neurology. — 2005. — Vol. 65. —

P. 138-140.

Shinoda K., Murai H., Shibata K. et al. Overlap case of Fisher syndrome and pharyngeal-cervical-brachial variant of Guillain-Barré syndrome // Rinsho Shinkeigaku. — 2012. — Vol. 52 (1). — P. 30-33.

Terenghi F., Cappellari A., Bersano A., Carpo M., Bar­bieri S., Nobile-Orazio E. How long is IVIG effective in multifocal motor neuropathy? // Neurology. — 2004. — Vol. 62. — P. 666-668.

The Guillain-Barré Syndrome Study Group. Plasma-pheresis and acute Guillain-Barré syndrome // Neurology. — 1985. — Vol. 35. — P. 1096-1104.

Thompson N., Choudhary P.P., Hughes R.A.C., Quinlivan R.M. A novel trial design tostudy the effect of intra-venous immunoglobulin in chronic inflammatory demy-elinatingpolyradiculoneuropathy // Journal of Neurology. — 1996. — Vol. 243. — P. 280-285.

Van den Berg L.H., Franssen H., Wokke J.H.J. The long-term effect of intravenous immunoglobulintreatment in multifocal motor neuropathy // Brain. — 1998. — Vol. 121. — P. 421-428.

Van den Berg L.H., Kerkhoff H., Oey P.L. et al. Treatment of multifocal motor neuropathywith high dose intravenous immunoglobulins: a double blind, placebo controlled study // Journal of Neurology, Neurosurgery and Psychiatry. — 1995. — Vol. 59. — P. 248-252.

Van den Berg L.H., Lokhorst H., Wokke J.H. Pulsed high-dose dexamethasone isnot effective in patients with multifocal motor neuropathy [comment] // Neurology. — 1997. — Vol. 48. — P. 1135.

Van den Berg-Vos R.M., Franssen H., Wokke J.H.J.,

Van Es.H.W., Van den Berg L.H. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment // Annals of Neurology. — 2000. — Vol. 48. — P. 919-926.

Van der Meche F.G.A., Schmitz P.I.M. The Dutch Guillain-Barré Study Group. A randomizedtrial comparing intravenous immune globulin and plasma exchange in Guillain-Barrésyndrome // New England Journal of Medicine. — 1992. — Vol. 326. — P. 1123-1129.

Van Doorn P.A., Dippel D.W.J., Vermeulen M. Longterm iv immunoglobulin treatment inchronic inflammatory demyelinating polyneuropathy // Journal of the Peripheral Nervous System. — 2007. — Vol. 12. — P. 89.

Van Doorn P.A., Kuitwaard K., Jacobs B.C. et al. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP // J. Peripher. Nerv. Syst. — 2011. — Vol. 1. — P. 38-40.

Van Koningsveld R., Schmitz P.I.M., Van der Meche F.G.A. et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial // Lancet. — 2004. — Vol. 363. — P. 192-196.

Van Schaik I.N., van den Berg L.H., de Haan R., Vermeulen M. Intravenous immunoglobulinefor multifocal motor neuropathy // Cochrane Database of Systematic Reviews. — 2005. — Vol. 2. — CD004429.

Van Schaik I.N., Winer J.B., de Haan R., Vermeulen M. Intravenous immunoglobulinefor chronic inflammatory demyelinating polyradiculoneuropathy // Cochrane Database of Systematic Reviews. — 2004. — Vol. 2. — P. CD001797.

Vermeulen M., Van Doorn P.A., Brand A., Strengers P.F.W., Jennekens F.G.I., Busch H.F.M. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinatingpolyneuropathy // Journal of Neurology, Neurosurgery and Psychiatry. — 1993. — Vol. 56. — P. 36-39.

Vucic S., Black K.R., Chong P.S.T., Cros D. Multifocal motor neuropathy. Decrease in conductionblocks and reinnervation with long-term IVIG // Neurology. — 2004. — Vol. 63. — P. 1264-1269.

Wang R., Feng A., Sun W., Wen Z. Intravenous immunoglobulin in children with Guillain-Barré syndrome // Journal of Applied Clinical Pediatrics. — 2001. — Vol. 16. — P. 223-224.

Winer J.B., Hughes R.A.C., Osmond C. A prospective study of acute idiopathic neuropathy.I. Clinical features and their prognostic value // Journal of Neurology, Neurosurgeryand Psychiatry. — 1988. — Vol. 51. — P. 605-612.

Yepishin I.V., Allison R.Z., Kaminskas D.A. et al. Miller Fisher Syndrome: A Case Report Highlighting Heterogeneity of Clinical Features and Focused Differential Diagnosis // Hawaii J. Med. Public. Health. — 2016. — Vol. 75 (7). — P. 196-199.

Yuki N., Ang C.W., Koga M. et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside // Annals of Neurology. — 2000. — Vol. 47. — P. 314-321.

Zhang G., Massaad C.A., Gao T. et al. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury // Exp. Neurol. — 2016. — Vol. 282. — P. 49-55.




Copyright (c) 2017 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта